

Sunil Healthcare Limited

June 27, 2023

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long Term Bank Facilities	34.08 (Reduced from 35.46)	CARE BBB; Negative	Reaffirmed; Outlook revised from Stable
Short Term Bank Facilities	20.85	CARE A3	Revised from CARE A3+

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

The reaffirmation of long-term rating and revision in short-term rating assigned to the bank facilities of Sunil Healthcare Limited (SHL) takes into account declining profitability quarter-on-quarter basis during FY23 (Provisional, refers to the period of April 01 to March 31) owing to decline in prices, increase in competition and softening of demand. The ratings, however, continues to derive strengths from experienced and resourceful promoters along with long track record of operations leading to established brand name along with wide range of product & revenue stream, established relationship with diversified and reputed clientele albeit customer concentration risk & comfortable capital structure.

However, the rating strengths are partially offset by exposure to raw material price volatility and foreign currency fluctuations risk coupled with highly fragmented and competitive nature of industry with regulatory risks.

Rating sensitivities: Factors likely to lead to rating actions.

Positive factors

- Sustained improvement in scale of operations with total operating income beyond Rs.150 crores.
- Improvement in Improvement in profitability margins marked by PBILDT margin exceeding 18% coupled with ROCE of over 17% on sustained basis.

Negative factors

- PBILDT margins falling below ~10% on a sustained basis.
- Any major debt funded capex or increase in working capital borrowings resulting in deterioration of overall gearing ratio to above 1.5x.

Analytical approach: Standalone

Outlook: Negative

The Outlook for the long-term facilities of Sunil Healthcare Ltd is proposed to be revised from "Stable" to "Negative" on account of expected deterioration in the financial risk profile of the company owing to increased competition in the industry thereby creating pressure on pricing of capsules. Due to excess supply and limited demand, there is decline in the pricing for its products from Q3FY23 onwards as can be seen in the performance for Q3 and Q4 of FY23. Further pricing pressure remain in Q1 and expected to continue at least till Q2FY24. The ratings may be revised downwards if profitability of the company continue to deteriorate from the expected level leading to deterioration of liquidity position in terms of higher working capital utilization or incremental debt to support the losses. The outlook may be revised to 'Stable' if the company is able to sustain its scale of operations while maintaining its capital structure and profitability margins.

Detailed description of the key rating drivers:

Key strengths

Experienced and resourceful promoters along with long track record of operations:

SHL is promoted by Mr. Anil Khaitan (Chairman and Managing Director) who has nearly four decades of industry experience and is involved in the overall business operations of the company. The directors of the company are assisted by a team of professionals who are highly experienced in their respective domains.

Established brand name:

SHL is one of the leading EHGC (Empty Hard Gelatin Capsules) shell manufacturer in the domestic market, company sells its products under the brand name, 'Sunloc' which enjoys decent credibility in domestic as well as in foreign markets. Although, there is presence of multiple small players and few large players in the industry making it highly competitive industry.

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

Wide range of product & revenue stream:

The company's product profile is well diversified with production of double lock, triple lock, multiple groove capsules of EHGC (Empty Hard Gelatin Capsule) & some proportion of vegan HPMC (Hydroxy Propyl Methyl Cellulose) along with liner, circular, two-colour printing & 360degree printing being offered. Since, the pricing of HPMC remains almost three times of gelatin capsules manufactured by the company which is ultimately used by pharma industry which are highly regulated, and pricing is also controlled under Drug (Prices Control) Order, 2013. This leads to lower demand of HPMC capsules due to its higher pricing. The proportion of HPMC capsules in total revenue from operations of company is not likely to increase substantially during years to come.

Established relationship with diversified and reputed clientele albeit customer concentration risk.

Over the period, SHL has established a reputed customer base, both in the domestic and export markets which include reputed Active Pharmaceutical Ingredients (APIs) and Pharma manufacturers. During FY23, about 44.84% of the total income of the company was derived from top 5 buyers which is increased from 22.60% during FY22 leading to customer concentration risk to some extent. However, company attempts to retain the customers having long relationship of long relationship and they are getting regular order from these buyers.

Further, company imports raw materials (Gelatin) and also procure domestically which is then processed at the sole manufacturing facility of company. Top 5 suppliers collectively comprise almost 88.30% of total raw material procured during the FY23 which has been reduced from 95.43% during FY22.

Comfortable Capital Structure

The capital structure of the company remains comfortable during FY23 as reflected by the long-term debt to equity ratio and overall gearing ratio of 0.24x and 0.87x, respectively, as of March 31, 2023, as against long-term debt to equity ratio and overall gearing ratio of 0.30x and 0.83x, respectively, as of March 31, 2022. Although, due to declining price of capsules owing to increased competition in the industry (the realisation per capsules in Q4FY23 which is continued in Q1FY24 has been reduced by almost ~23% as compared to realisation per capsule in Q1FY23). Thus, company has availed long term loan in May 31, 2023, payable in 60 months after expiry of moratorium period of 3 months for reimbursement of capex done from internal accruals during preceding financial year/s which will further improve liquidity position of company.

Key weaknesses**Small scale of operations coupled with declining profitability quarter on quarter basis.**

Scale of operations remain small at Rs 113.46 crores during FY23 (Provisional, refers to the period of April 01 to March 31) which remains in similar line as compared to preceding financial year since company had booked revenue from operations of Rs. 116.96 crores during FY22 (Audited, refers to the period of April 01 to March 31). Further, company majorly caters domestic market with some proportion of exports which comprises 24% during FY23 (PY: 25% during FY22).

The profitability margin of the company has shown a declining trend quarter on quarter basis during FY23 majorly due to increased competition between capsule manufacturing entities thereby creating severe pressure on pricing of end products i.e., gelatin capsules. Thus, sales prices of each capsule have been reduced by almost ~23% in Q4FY23 (continued in current financial year as well) as compared to realisation per capsule in Q1FY23 leading to declining PBILD margin on quarter-on-quarter basis. The pricing pressure is likely to continue in Q1FY24 and probably in first half of the current financial year. Thus, company has availed long term funding which will counter the liquidity impact created by pricing pressure on gelatin capsules.

Although, the profitability margins of the entity remain moderate on annual basis as reflected by PBILD margin and PAT margin of 18.45% (PY: 15.73%) and 6.15% (PY: 5.79%) respectively which is majorly supported by higher profitability during Q1FY23. Thus, company has booked gross cash accruals of Rs. 15.09 crores during FY23 as compared to Rs. 15.87 crores during FY22. Interest coverage indicator also remains moderate and in similar line which stands at 5.02 times during FY23 as compared to 5.27 times in FY22.

Highly fragmented and competitive nature of industry with regulatory risks:

SHL is engaged in the manufacturing of capsule shells which is a raw material (excipient category) for pharmaceutical and food supplement industry. The industry is characterized by a high level of competition having presence of multiple small and few big players. Further, pharmaceutical industry is a closely monitored and regulated industry and as such there are inherent risks and liabilities associated with the products and their manufacturing. Issues like price control of essential medicines by the Government of India through the Drug (Prices Control) Order, 2013, pose regulatory risk for the pharmaceutical industry. Although, empty capsules shells are of excipient category in Drug (Prices Control) Order, 2013 but majority of final products manufactured using these capsules are highly regulated. Also in the last 1-2 years, there has been significant addition in capacities by several players, leading to oversupply in the industry and this has impacted the selling price adversely and the same has declined by more than 20% in the last 9 months. Going forward, the prices are expected to remain moderate at least in the next 3-4 months. Therefore, the ability of the company to manage the competition along with the pressure on selling prices will be key monitorable from the credit rating perspective.

Exposure to raw material price volatility and foreign currency fluctuations risk:

The raw materials, primarily gelatin, colour & chemical compounds, are obtained from both domestic and foreign suppliers. Due to competitive nature of the industry, the company is not always able to pass on any increase input costs to its customers, thus, the profitability margins are exposed to any adverse fluctuation in raw material prices. The company has identified certain new source of raw material procurement at cheaper cost, to mitigate the impact of decline in selling prices, however the saving on raw material procurement is not sufficient to completely absorb the declining realisation per capsule. Therefore, going forward any adverse movement in the raw material prices, will have a major impact on the company profitability and liquidity position. Moreover, the foreign currency exposure of SHL is naturally hedged to an extent as the company is engaged in both import of raw material and exports of its products. The company also enters derivative contracts to hedge some part of its unhedged portion, therefore the remaining portion remains unhedged thereby exposing the profitability margins to adverse fluctuations in foreign exchange rates. However, the company has reported foreign currency fluctuation gains during FY23 as well as FY22.

Liquidity: Adequate

The company has earned Gross Cash Accruals (GCA) of Rs. 15.09 crores during FY23 and is projecting to generate GCA of around Rs ~8 crores & Rs ~11 crores in FY24 & FY25 respectively as against scheduled repayment obligations of Rs. 3.97 crores and Rs. 5.11 crores for FY24 & FY25 respectively. The current and quick ratio stood at a moderate level of 1.13x and 0.85x, as on March 31, 2023, which is improved from 0.90x and 0.63x respectively as on March 31, 2022. Moreover, since company has availed long term funding, this will further improve liquidity. Furthermore, operating cycle continues to remain moderate at 92 days during FY23 as against 83 days during FY22 owing to which average working capital utilisation of cash credit limits of the company remains comparatively low and stood at 57.76% during the 12 months ending April 2023.

Environment, social, and governance (ESG) risks: Not Applicable

Applicable criteria

[Policy on default recognition](#)

[Financial Ratios – Non financial Sector](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Credit Watch](#)

[Short Term Instruments](#)

[Manufacturing Companies](#)

[Pharmaceutical](#)

[Policy on Withdrawal of Ratings](#)

About the company and industry

Industry classification

Macro-Economic Indicator	Sector	Industry	Basic Industry
Healthcare	Healthcare	Healthcare Equipment & Supplies	Medical Equipment & Supplies

SHL was incorporated in 1973 by Late Mr. S.N Khaitan, the father of Mr. Anil Khaitan, who is the present Chairman and Managing Director of the company. SHL was originally constituted as a closely held public limited company by the name of Sunil Synchem Limited, however, the same was changed in June-2005 to its current name. SHL is mainly engaged in the manufacturing of Empty Hard Gelatin Capsule (EHGC) shells and Hydroxypropyl Methylcellulose (HPMC) at its sole unit at Alwar, Rajasthan. The company was earlier also engaged in the trading (including merchant trading) of agro based commodities since 2013, under brand 'Sunloc foods'. However, the same has been discontinued in FY20 (since July 01, 2019).

Brief Financials (₹ crore)	March 31, 2021 (A)	March 31, 2022 (A)	March 31, 2023 (UA)
Total operating income	89.75	116.96	113.46
PBILDT	6.33	18.40	20.94
PAT	0.28	6.78	6.98
Overall gearing (times)	1.37	0.83	0.87
Interest coverage (times)	1.19	5.27	5.02

A: Audited UA: Unaudited; Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT-Cash Credit		-	-	-	28.50	CARE BBB; Negative
Fund-based - LT-Term Loan		-	-	November 2026	5.58	CARE BBB; Negative
Non-fund-based - ST-BG/LC		-	-	-	20.25	CARE A3
Non-fund-based - ST-Forward Contract		-	-	-	0.60	CARE A3

Annexure-2: Rating history for the last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021
1	Fund-based - LT-Cash Credit	LT	28.50	CARE BBB; Negative	-	1)CARE BBB; Stable (16-Feb-23) 2)CARE BBB; Stable (01-Jul-22)	1)CARE BBB-; Stable (26-Nov-21)	1)CARE BBB-; Negative (05-Oct-20)
2	Fund-based - LT-Stand by Limits	LT	-	-	-	-	1)Withdrawn (26-Nov-21)	1)CARE BBB-; Negative (05-Oct-20)
3	Non-fund-based - ST-BG/LC	ST	20.25	CARE A3	-	1)CARE A3+ (16-Feb-23) 2)CARE A3+ (01-Jul-22)	1)CARE A3 (26-Nov-21)	1)CARE A3 (05-Oct-20)
4	Non-fund-based - ST-Forward Contract	ST	0.60	CARE A3	-	1)CARE A3+ (16-Feb-23) 2)CARE A3+ (01-Jul-22)	1)CARE A3 (26-Nov-21)	1)CARE A3 (05-Oct-20)
5	Fund-based - ST-Standby Line of Credit	ST	-	-	-	1)Withdrawn (01-Jul-22)	1)CARE A3 (26-Nov-21)	1)CARE A3 (05-Oct-20)
6	Fund-based - ST-Working Capital Demand loan	ST	-	-	-	-	1)Withdrawn (26-Nov-21)	1)CARE A3 (05-Oct-20)
7	Fund-based - LT-Term Loan	LT	5.58	CARE BBB; Negative	-	1)CARE BBB; Stable (16-Feb-23) 2)CARE BBB; Stable (01-Jul-22)	1)CARE BBB-; Stable (26-Nov-21)	1)CARE BBB-; Negative (05-Oct-20)

*Long term/Short term.

Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not Applicable**Annexure-4: Complexity level of the various instruments rated**

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Cash Credit	Simple
2	Fund-based - LT-Term Loan	Simple
3	Non-fund-based - ST-BG/LC	Simple
4	Non-fund-based - ST-Forward Contract	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please [click here](#)

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Contact us

<p>Media Contact</p> <p>Name: Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3573 E-mail: mradul.mishra@careedge.in</p> <p>Relationship Contact</p> <p>Name: Dinesh Sharma Director CARE Ratings Limited Phone: +91-120-445 2005 E-mail: dinesh.sharma@careedge.in</p>	<p>Analytical Contacts</p> <p>Name: Sajan Goyal Director CARE Ratings Limited Phone: +91- 120-445 2017 E-mail: sajan.goyal@careedge.in</p> <p>Name: Amit Jindal Assistant Director CARE Ratings Limited Phone: +91- 120-445 2073 E-mail: amit.jindal@careedge.in</p> <p>Name: Farhan Anwar Lead Analyst CARE Ratings Limited E-mail: farhan.anwar@careedge.in</p>
--	---

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,
please visit www.careedge.in**